CHICAGO – A multimodal, artificial intelligence (AI)-driven model that analyzes routinely collected imaging and clinical information led to more accurate prediction of cancer cachexia than standard ...
Cancer cachexia is a multifactorial syndrome characterized by skeletal muscle loss leading to progressive functional impairment. Despite the ubiquity of cachexia in clinical practice, prevention, ...
New research from the University of Oklahoma, published today in Cancer Cell, describes for the first time a "triangle ...
Cancer cachexia is a complex metabolic syndrome characterized by the ongoing loss of skeletal muscle mass, with or without fat loss, that cannot be reversed entirely by conventional nutritional ...
Hosted on MSN
Essay addressing cachexia emphasizes that patient reports aren't anecdotal; they're valuable data
Janowitz's essay not only points to new potential therapeutic strategies for cancer cachexia and other diseases. It calls for closer collaboration between cancer researchers and neuroscientists.
Add Yahoo as a preferred source to see more of our stories on Google. Poorly functioning blood vessels lead to the characteristic muscle weakness that so many cancer patients experience. Artur ...
Hosted on MSN
Artelo’s cancer cachexia drug succeeds in Phase II
Artelo Biosciences’ cancer anorexia-cachexia syndrome (CACS) drug has helped patients gain weight in a Phase II trial. During the CAReS study (EudraCT-2020-000464-27), ART27.13, a cannabinoid receptor ...
Consistent Improvements in Weight Gain, Lean Body Mass, and Activity were Observed Across Treated Patients including +6.4% Mean Weight Gain at 12 Weeks vs −5.4% Mean Weight Loss on Placebo The Phase 2 ...
S2408: A randomized phase III blinded trial of lanreotide for the prevention of postoperative pancreatic fistula. Primary endpoints Percent change from BL in body weight at Week 12 Change from BL in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results